Medical device maker Medtronic (MDT) reported a solid quarter Tuesday morning, but its stock was down a fraction on the stock market today as its profit margins showed signs of weakness. For its fiscal Q2 ended Oct. 25, Medtronic made 91 cents a share, up 3.4% from the year-earlier quarter and a penny over analysts’ consensus. Sales rose 2.4% to $4.2 billion, in line with consensus. The company reiterated its guidance for the full fiscal year,
Would acquiring Vodafone be the cure for AT&T’s growth malady? Consider the patient. AT&T’s (T) Q3 revenue rose just 2%, missing views. Sales for its wireless services, its presumed growth engine, also missed, up 3.7%. AT&T’s annual revenue hasn’t risen more than 4% since 2007. Now mull the widely speculated prescription: buying Vodafone (VOD), after the U.K. company completes the sale of its 45% stake in Verizon Wireless for $130 billion to
Medical device giant Medtronic (MDT) was trading near a 13-year high Monday as the company prepared to report its fiscal Q2 results before the open Tuesday. Analysts polled by Thomson Reuters estimate that Medtronic made 90 cents a share in the quarter ended Oct. 25, up 2% from the year-earlier quarter. Sales are also estimated to have risen 2%, to $4.18 billion. Medtronic stock on Thursday hit its highest point since January 2006, at 58.85, after